PMID- 34288728
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20240403
IS  - 1098-660X (Electronic)
IS  - 0095-1137 (Print)
IS  - 0095-1137 (Linking)
VI  - 59
IP  - 11
DP  - 2021 Oct 19
TI  - Multicenter Postimplementation Assessment of the Positive Predictive Value of 
      SARS-CoV-2 Antigen-Based Point-of-Care Tests Used for Screening of Asymptomatic 
      Continuing Care Staff.
PG  - e0141121
LID - 10.1128/JCM.01411-21 [doi]
LID - e01411-21
AB  - Frequent screening of severe acute respiratory syndrome coronavirus 2 
      (SARS-CoV-2) among asymptomatic populations using antigen-based point-of-care 
      tests (APOCTs) is occurring globally with limited clinical performance data. The 
      positive predictive value (PPV) of two APOCTs used in the asymptomatic screening 
      of SARS-CoV-2 among health care workers (HCWs) at continuing care (CC) sites 
      across AB, Canada, was evaluated. Between 22 February and 2 May 2021, CC sites 
      implemented SARS-CoV-2 voluntary screening of their asymptomatic HCWs. On-site 
      testing with Abbott Panbio or BD Veritor occurred on a weekly or twice-weekly 
      basis. Positive APOCTs were confirmed with a real-time reverse transcriptase PCR 
      (rRT-PCR) reference method. A total of 71,847 APOCTs (17,689 Veritor and 54,158 
      Panbio) were performed among 369 CC sites. Eighty-seven (0.12%) APOCTs were 
      positive, of which 39 (0.05%) were confirmed as true positives using rRT-PCR. Use 
      of the Veritor and Panbio resulted in 76.6% and 30.0% false-positive detection, 
      respectively (P < 0.001). This corresponded to PPVs of 23.4 and 70.0% for the 
      Veritor and Panbio, respectively. Frequent screening of SARS-CoV-2 among 
      asymptomatic HCWs in CC, using APOCTs, resulted in a very low detection rate and 
      a high rate of detection of false positives. Careful assessment of the risks 
      versus benefits of APOCT programs and the prevalence of infection in this 
      population needs to be thoroughly considered before implementation.
FAU - Kanji, Jamil N
AU  - Kanji JN
AUID- ORCID: 0000-0002-1043-6807
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Calgarygrid.22072.35 School of Medicine, Calgary Alberta, Canada.
AD  - Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada.
AD  - Department of Laboratory Medicine and Pathology, Faculty of Medicine and 
      Dentistry, University of Albertagrid.17089.37, Edmonton, Alberta, Canada.
AD  - Department of Pathology and Laboratory Medicine, University of 
      Calgarygrid.22072.35 School of Medicine, Calgary, Alberta, Canada.
FAU - Proctor, Dustin T
AU  - Proctor DT
AD  - Department of Pathology and Laboratory Medicine, University of 
      Calgarygrid.22072.35 School of Medicine, Calgary, Alberta, Canada.
AD  - Clinical Biochemistry, Alberta Precision Laboratories, Diagnostic and Scientific 
      Center, Calgary, Alberta, Canada.
FAU - Stokes, William
AU  - Stokes W
AUID- ORCID: 0000-0002-8684-0494
AD  - Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada.
AD  - Department of Laboratory Medicine and Pathology, Faculty of Medicine and 
      Dentistry, University of Albertagrid.17089.37, Edmonton, Alberta, Canada.
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Albertagrid.17089.37, Edmonton, Alberta, Canada.
FAU - Berenger, Byron M
AU  - Berenger BM
AUID- ORCID: 0000-0001-9062-6346
AD  - Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada.
AD  - Department of Pathology and Laboratory Medicine, University of 
      Calgarygrid.22072.35 School of Medicine, Calgary, Alberta, Canada.
FAU - Silvius, James
AU  - Silvius J
AD  - Division of Geriatric Medicine, Cumming School of Medicine, Calgary, Alberta, 
      Canada.
FAU - Tipples, Graham
AU  - Tipples G
AD  - Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada.
AD  - Li Ka Shing Institute of Virology, University of Albertagrid.17089.37, Edmonton, 
      Alberta, Canada.
AD  - Department of Medical Microbiology and Immunology, Faculty of Medicine and 
      Dentistry, University of Albertagrid.17089.37, Edmonton, Alberta, Canada.
FAU - Joffe, A Mark
AU  - Joffe AM
AD  - Division of Infectious Diseases, Department of Medicine, University of 
      Albertagrid.17089.37, Edmonton, Alberta, Canada.
AD  - Alberta Health Services, Edmonton, Alberta, Canada.
FAU - Venner, Allison A
AU  - Venner AA
AD  - Department of Pathology and Laboratory Medicine, University of 
      Calgarygrid.22072.35 School of Medicine, Calgary, Alberta, Canada.
AD  - Clinical Biochemistry, Alberta Precision Laboratories, Diagnostic and Scientific 
      Center, Calgary, Alberta, Canada.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20210721
PL  - United States
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
SB  - IM
MH  - *COVID-19
MH  - Humans
MH  - Point-of-Care Testing
MH  - Predictive Value of Tests
MH  - *SARS-CoV-2
MH  - Sensitivity and Specificity
PMC - PMC8525574
OTO - NOTNLM
OT  - SARS-CoV-2 antigen
OT  - point of care
OT  - positive predictive value
OT  - sensitivity
EDAT- 2021/07/22 06:00
MHDA- 2021/10/28 06:00
PMCR- 2021/10/19
CRDT- 2021/07/21 17:17
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/07/21 17:17 [entrez]
PHST- 2021/10/19 00:00 [pmc-release]
AID - 01411-21 [pii]
AID - jcm.01411-21 [pii]
AID - 10.1128/JCM.01411-21 [doi]
PST - ppublish
SO  - J Clin Microbiol. 2021 Oct 19;59(11):e0141121. doi: 10.1128/JCM.01411-21. Epub 
      2021 Jul 21.